Marcus Vetter

Head of Department

University Hospital Basel
Country flagSwitzerland

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Marcus Vetter is an Assistant Professor at University Hospital Basel in Switzerland. His research primarily focuses on oncology, particularly in the areas of metastatic breast cancer treatment, machine learning applications in patient-reported outcomes, and the management of cancer therapy-related side effects. His recent publications reflect a commitment to improving personalized treatment approaches and understanding the prognostic factors in breast cancer and gynecological cancers.

Articles (22)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

In patients with hormone receptor positive, human epidermal receptor 2 negative (HR+/HER2−) negative breast cancer (BC), the TAILORx study showed the benefit of adding chemotherapy (CHT) to endocrine therapy (ET) in a subgroup of patients under 50 years with an intermediate Oncotype DX recurrence score (RS 11–25). The aim of the present study was to determine if the TAILORx findings, including the changes in the RS categories, impacted CHT use in the intermediate RS (11–25) group in daily practice, as well as to identify the main factors for CHT decisions. We conducted a retrospective study on 326 BC patients (59% node-negative), of which 165 had a BC diagnosis before TAILORx (Cohort A) and 161 after TAILORx publication (Cohort B). Changes in the RS categories led to shifts in patient population distribution, thereby leading to a 40% drop in the low RS (from 60% to 20%), which represented a doubling in the intermediate RS (from 30% to 60%) and an increase of 5% in the high RS (from 8–10% to 15%). The overall CHT recommendation and application did not differ significantly between cohort B when compared with A (19% vs. 22%, resp., p = 0.763). In the intermediate RS (11–25), CHT use decreased by 5%, while in the high-risk RS category (>25), there was an increase of 13%. The tumor board recommended CHT for 90% of the patients according to the new RS guidelines in cohort A and for 85% in cohort B. The decision for CHT recommendation was based on age (OR 0.93, 95% CI 0.08–0.97, p = 0.001), nodal stage (OR 4.77, 95% CI 2.03–11.22, p < 0.001), and RS categories (RS 11–25 vs. RS 0–10: OR 0.06 (95% CI 0.02–0.17), p < 0.001; RS > 26 vs. RS 11–25: OR 618.18 95% CI 91.64–4169.91, p < 0.001), but did not depend on the cohort. In conclusion, while the tumor board recommendation for CHT decreased in the intermediate RS category, there was an increase being reported in the high RS category, thus leading to overall minor changes in CHT application. As expected, among the younger women with intermediate RS and unfavorable histopathological factors, CHT use increased.

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (20)

Andreas Mueller

Dr. med.; Head of Breast Center

-

SWITZERLAND
View details

Céline Montavon

-

SWITZERLAND
View details

Céline Bolliger

University of Lucerne

SWITZERLAND
View details

Michael Krauthammer

Professor

University of Zurich

SWITZERLAND
View details

Markus Felix Templin

Natural and Medical Sciences Institute

GERMANY
View details

Cvetka Grašič Kuhar

-

SWITZERLAND
View details

Ralf Kühn

Max Delbrück Centrum für Molekulare Medizin Berlin Buch

GERMANY
View details

Kathrin Scherer

University of Basel

SWITZERLAND
View details

Francesc Castro-Giner

Head of Computational Biology

ETH Zürich

SWITZERLAND
View details

Kirsten Mertz

Head of Institute

University Hospital Basel

SWITZERLAND
View details

Walter Paul Weber

Co-leader

University Hospital Basel

SWITZERLAND
View details

Aleksandra Strojna

Kliniken Essen-Mitte Evangelische Huyssens-Stiftung/Knappschaft GmbH Klinik für Gynäkologie & Gynäkologische Onkologie

GERMANY
View details

Seyed Mohsen Mousavi

Head

-

SWITZERLAND
View details

Gaetana Restivo

University of Zurich

SWITZERLAND
View details

Michael Linnebacher

Research Leader

Rostock University Medical Center

GERMANY
View details

Gad Singer

Head of the Institute

-

SWITZERLAND
View details

Salvatore Piscuoglio

Associate Professor

Humanitas University

ITALY
View details

Mohamed Bentires-Alj

Professor of experimental surgical oncology

University of Basel

SWITZERLAND
View details

Zoia Razumova

Karolinska Institutet

SWEDEN
View details

Viola Heinzelmann-Schwarz

University Hospital Basel

SWITZERLAND
View details